WAM
CRDF icon

Wealthspire Advisors (Maryland)’s Cardiff Oncology CRDF Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-24
Closed – – 787
2019
Q1 		$0 Buy
+24
New +$86 ﹤0.01% 2495
2016
Q3 		– Sell
-36
Closed -$12K – 1739
2016
Q2 		$12K Buy
+36
New +$12.4K ﹤0.01% 1155

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s CRDF Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Cardiff Oncology (CRDF) in Q2 2019, closing a stake of 24 shares.

Wealthspire Advisors (Maryland) first reported a position in CRDF in Q2 2016 and held it in 2 quarters. The position peaked at $12K in Q2 2016. 23 funds tracked by Wall St. Rank hold CRDF as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Cardiff Oncology position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 24 Cardiff Oncology shares in Q2 2019.
  • Wealthspire Advisors (Maryland) first reported a position in Cardiff Oncology in Q2 2016 and held it in 2 quarters.
  • Wealthspire Advisors (Maryland)'s Cardiff Oncology position peaked at $12K in Q2 2016.
  • 23 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.